Outcomes

The available evidence for tesamorelin outcomes is primarily drawn from completed clinical trials and emerging research, though specific measurable results are limited in the provided literature.

Body Composition and Metabolic Effects

Based on completed clinical trials, tesamorelin has been studied for reducing abdominal fat in people with obesity (NCT00675506) and for addressing visceral abdominal fat in people living with HIV. Case reports from 2026 describe distinct therapeutic outcomes when tesamorelin is used versus GLP-1 receptor agonists for excess visceral abdominal fat in HIV patients, though specific measurements are not detailed in the available evidence.

One completed study (NCT02196831) examined tesamorelin's effects on liver fat and histology in HIV patients, though outcome data is not provided in the current evidence base.

Physical Function Outcomes

A clinical trial protocol (TRIUMPH study) describes plans to evaluate tesamorelin as an adjunct to exercise for improving physical function in HIV patients, but results are not yet available as this appears to be an ongoing or planned study.

Cognitive and Neurological Effects

Emerging research from 2026 investigated growth hormone-releasing hormone's (GHRH) effects on cognition and brain connectivity in adults ranging from normal cognition to mild cognitive impairment. However, specific cognitive outcome measures and results are not detailed in the available evidence.

Safety Profile

The literature references tesamorelin in the context of injectable peptides in sports medicine and performance enhancement, with discussions of safety and anti-doping implications, though specific adverse event data is not provided in the current evidence.

Evidence Limitations

The strength of evidence for specific measurable outcomes is limited in the provided materials. While multiple completed clinical trials are referenced, detailed outcome data, statistical significance, effect sizes, and comparative results are not available in the current evidence base. Most recent publications appear to be protocols, case reports, or review articles rather than completed outcome studies with quantitative results.

Note: This summary is based on limited evidence. Consult healthcare providers for complete outcome data and personalized medical guidance regarding tesamorelin therapy.

Tesamorelin

Member access required